The stock of Onconova Therapeutics Inc (NASDAQ:ONTX) is a huge mover today! About 104,219 shares traded hands or 91.78% up from the average. Onconova Therapeutics Inc (NASDAQ:ONTX) has declined 31.36% since April 13, 2016 and is downtrending. It has underperformed by 35.29% the S&P500.
The move comes after 5 months negative chart setup for the $19.36M company. It was reported on Nov, 15 by Barchart.com. We have $2.45 PT which if reached, will make NASDAQ:ONTX worth $2.13M less.
According to Zacks Investment Research, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company’s products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania.”
More important recent Onconova Therapeutics Inc (NASDAQ:ONTX) news were published by: Nasdaq.com which released: “Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third …” on November 14, 2016, also Fool.com published article titled: “Why Onconova Therapeutics Inc. Shares Imploded”, Nasdaq.com published: “Onconova Therapeutics, Inc. to Present Corporate Update at 2016 BIO Investor Forum” on August 11, 2016. More interesting news about Onconova Therapeutics Inc (NASDAQ:ONTX) was released by: Fool.com and their article: “Why Onconova Therapeutics Inc. Shares Crashed” with publication date: December 18, 2013.
ONTX Company Profile
Onconova Therapeutics, Inc., incorporated on December 22, 1998, is a clinical-stage biopharmaceutical company. The Firm operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Firm has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.